Given its role in tumor biology, USP22 is being explored as a potential therapeutic target, aiming to develop novel inhibitors that could enhance the effectiveness of existing treatments and improve outcomes for NSCLC patients [38]. This evidence concerns the gene USP22 and neoplasm.